Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations
NCT03764722
·
clinicaltrials.gov ↗
PHASE4
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Systolic Heart Failure
Interventions
DRUG:
Levosimendan
Sponsor
Collegium Medicum w Bydgoszczy